Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced that its Comirnaty bivalent vaccine has been approved as a normal import vaccine in Macau. The vaccine is authorized for use as a booster shot in individuals aged 12 and above.
Partnership and Development
Fosun Pharma is partnered with Germany’s BioNTech (NASDAQ: BNTX) on the development of Comirnaty in the Greater China region. The product was previously approved for immunization in Hong Kong and Macau, followed by Taiwan in March and September 2021, respectively. The Comirnaty bivalent vaccine, licensed by Fosun Pharma, is an updated version of the original Comirnaty vaccine, incorporating mRNA encoding spike proteins from both the original strain and the Omicron BA.4/BA.5 variants.
Vaccine Composition and Previous Approvals
Each dose of the bivalent vaccine contains micrograms of mRNA encoding the spike protein of the original strain and 15 micrograms of mRNA encoding the spike protein of the Omicron BA.4/BA.5 variants. This formulation aims to provide broader protection against both the original and mutated strains of the virus. The vaccine has previously been approved for import and vaccination in Macau and Taiwan.-Fineline Info & Tech
